Month: January 2025

New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn CARLSBAD, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced it has received conditional approval from the New York State Department of Health for its new systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) biomarker assays, with a planned commercial launch in January 2025.  The company also announced preliminary unaudited select financial results for the fourth quarter and full year ended December 31, 2024, in line with prior financial guidance. New AVISE CTD Biomarkers The company’s new SLE and RA biomarkers will be incorporated...

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung Disease, receives positive EMA opinion on European Orphan Designation Application; European Commission expected to issue final decision in first quarter 2025 LONDON, Jan. 12, 2025 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on its lead clinical programs, setrusumab, a monoclonal antibody in Phase 3 clinical development for the treatment of Osteogenesis Imperfecta (OI) through a partnership with Ultragenyx Pharmaceutical, Inc. (Ultragenyx) and alvelestat, an oral neutrophil elastase inhibitor being studied...

Preliminary 2024 total revenue of $555 million to $560 million, exceeding top end of guidance, including Crysvita® revenue of $405 million to $410 million, and Dojolvi® revenue of $87 million to $89 million 2025 expected total revenue guidance of $640 million to $670 million UX143 (setrusumab) Phase 3 Orbit study for osteogenesis imperfecta progressing to second interim analysis in mid-2025 GTX-102 Phase 3 Aspire study for Angelman syndrome expected to complete enrollment in second half of 2025 NOVATO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today reported preliminary unaudited 2024 revenue results, cash and investments at year end 2024,...

ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) — (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2024 and provided full-year 2025 guidance. Preliminary Unaudited Fourth Quarter and Full-year 2024 ResultsPreliminary unaudited fourth quarter 2024 revenue is expected to be approximately $40.2 million, representing growth of approximately 41% compared to the prior year period, driven by:The sale of 29,069 Light Adjustable Lenses (LAL™/LAL+®); representing a 61% increase in procedure volume compared to the fourth quarter of 2023; and The sale of 83 Light Delivery Devices (LDD™s), expanding...

Preliminary unaudited product revenue for the fourth quarter of 2024 is expected to be approximately $63 million, up approximately 366% vs. Q4 2023 and 41% vs. Q3 2024 Preliminary unaudited product revenue for the full-year 2024 is expected to be approximately $160 million, up approximately 449% vs. 2023 Robust unit growth across the portfolio with gross-to-net (GTN) similar to prior quarter Preliminary unaudited cash, cash equivalents, restricted cash, and marketable securities as of December 31, 2024 are expected to be approximately $229 million Company to release complete fourth quarter and full year 2024 financial results and host a conference call and webcast on February 25, 2025 at 4:30 p.m. ESTWESTLAKE VILLAGE, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical...

Explore E Ink’s Latest Retail Display Technology at Partner Booths, Featuring Enhanced Color and Low Power Consumption BILLERICA, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) — E Ink (8069.TWO), the originator, pioneer, and global commercial leader in ePaper technology, today announced they will be showing a portfolio of E Ink Spectra™ 6 full-color ePaper retail signage at several partner booths during NRF 2025. Attendees of Retail’s Biggest Show can experience E Ink Spectra 6 products at the Javits Center in New York City from January 12-14 in the VusionGroup booth (#4938), the SoluM booth (#4457), and the Hanshow booth (#5957).“Following last year’s Spectra 6 recognition as Display of the Year, we are building on that momentum at this year’s NRF event by showcasing a large portfolio of displays across our larger network...

PASCAGOULA, Miss., Jan. 11, 2025 (GLOBE NEWSWIRE) — HII (NYSE: HII) christened San Antonio-class amphibious transport dock Harrisburg (LPD 30) today at the company’s Ingalls Shipbuilding division. “Today is more than just a christening; it is a celebration of craftsmanship, commitment and the enduring purpose of the work we do every day at Ingalls,” Ingalls Shipbuilding President Brian Blanchette said. “Like its namesake, Harrisburg — with its rich history of strength, resilience and leadership — shares the same qualities reflected in our shipbuilders, whose dedication ensures the Navy and Marine Corps have the advanced ships they need to protect and defend our nation.” LPD 30 is named after Harrisburg, Pennsylvania’s capital city, and commemorates the city’s rich history and longstanding support of the United States military....

(2025-01-11) Kitron has received an order with a value of NOK 46 million from Thales Norway. Deliveries will start in the first quarter of 2026 and continue through the second quarter of 2026. Production will take place at Kitron’s plant in Arendal, Norway. “This order is strategically important for Kitron. It strengthens our cooperation with Thales and contributes to securing our position in the defence sector,” said Heine Østby, Managing Director, Kitron Norway. For further information, please contact:Peter Nilsson, President and CEO, tel. +47 948 40 850Heine Østby, Managing Director, Kitron Norway, tel. +47 472 42 606 E-mail: investorrelations@kitron.com Kitron is a leading Scandinavian electronics manufacturing services company for the Connectivity, Electrification, Industry, Medical devices and Defence/Aerospace sectors. The...